S-1/A: Onconetix Files Amendment for Potential $25 Million Equity Line of Credit

Onconetix, Inc. has filed an amendment to its registration statement to facilitate the potential sale of up to 6,250,000 shares of common stock through an equity line of credit with Keystone Capital Partners, LLC.

Summary

• Onconetix, Inc. has filed an amendment to its S-1 registration statement related to a potential equity line of credit (ELOC) with Keystone Capital Partners, LLC.
• The company may sell up to 6,250,000 shares of common stock to Keystone, potentially raising up to $25 million in gross proceeds.
• The actual proceeds may be less depending on the number of shares sold and the price at which they are sold.
• The company will not receive any proceeds from the resale of shares by Keystone.
• Onconetix is a commercial-stage biotechnology company focused on men's health and oncology, with a key product being Proclarix, a prostate cancer diagnostic test.
• The company has paused commercialization of ENTADFI, a prostate treatment, and is exploring strategic alternatives, including a potential sale.
• Onconetix has a working capital deficit of approximately $16.3 million and an accumulated deficit of approximately $86.0 million as of September 30, 2024.
• The company's cash balance was approximately $0.4 million as of December 5, 2024, which is held by its foreign subsidiary.
• The company believes its current cash balance is insufficient to fund operations through the end of December 2024 and will need to raise additional capital.
• Management has determined that the funds readily available under the ELOC will not be sufficient to sustain operations for the next 12 months.
• The company has incurred net losses since inception and expects to continue to incur net losses in the foreseeable future.
• The company completed a reverse stock split at a ratio of 1:40 on September 24, 2024.
• The company entered into a PIPE financing on October 2, 2024, raising $2.0 million in gross proceeds.
• The company is obligated to use 30% of the gross proceeds from the ELOC to redeem Series C Preferred Stock and 25% of net proceeds to pay down debt to Veru.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a working capital deficit, accumulated losses, and insufficient cash to fund operations. While there is potential for future revenue from Proclarix, the company's ability to continue as a going concern is in doubt, leading to a negative sentiment.

Positives

• The ELOC provides a potential source of funding up to $25 million.
• The company has a commercial-stage product, Proclarix, with CE marking for sale in the European Union.
• The company has secured a license agreement with LabCorp for the development and commercialization of Proclarix in the U.S.
• The company has obtained stockholder approval to issue shares to Keystone in excess of the Exchange Cap.

Negatives

• The company has a significant working capital deficit and accumulated deficit.
• The company's current cash balance is insufficient to fund operations through the end of December 2024.
• The company has paused commercialization of ENTADFI and may abandon the assets.
• The company is dependent on third parties for manufacturing and commercialization of its products.
• The company has incurred net losses since inception and expects to continue to incur net losses in the foreseeable future.
• The company has significant debt obligations, including amounts owed to Veru.
• The company's ability to continue as a going concern is in doubt.

Risks

• The company may not be able to access the full amount available under the ELOC.
• The purchase price of shares under the ELOC will fluctuate based on market prices, potentially leading to dilution and price declines.
• The company's dependence on third parties for manufacturing and commercialization poses risks.
• The company may not be able to raise sufficient additional capital to fund its operations.
• The company has significant debt obligations, including amounts owed to Veru, which could lead to legal action.
• The company's ability to continue as a going concern is in doubt.
• The company may not be able to achieve or maintain profitability.
• The company may be subject to litigation and damages for failure to pay amounts due to Veru.

Future Outlook

The company expects to generate revenue from sales of Proclarix by 2026, but anticipates expenses will increase substantially in connection with commercialization, hiring, operating as a public company, and protecting intellectual property. The company will need to raise additional capital to fund its operations.

Management Comments

• Management has determined that the funds readily available under the ELOC will not be sufficient to sustain operations for the next 12 months.
• The Company continues to search for a permanent Chief Executive Officer and Chief Financial Officer.

Industry Context

The company operates in the competitive biotechnology sector, focusing on men's health and oncology. The development and commercialization of diagnostic tests like Proclarix are subject to regulatory approvals and market acceptance. The company's financial challenges are not uncommon for early-stage biotech companies.

Comparison to Industry Standards

• The company's reliance on third-party manufacturing and distribution is a common practice in the biotech industry, similar to companies like Myriad Genetics and Exact Sciences.
• The company's focus on prostate cancer diagnostics aligns with the growing demand for personalized medicine and early detection, similar to companies like Genomic Health.
• The company's financial situation, with significant losses and a need for additional capital, is typical for early-stage biotech companies, comparable to companies like Novavax and Sorrento Therapeutics.
• The company's decision to pause commercialization of ENTADFI and explore strategic alternatives is a common response to financial constraints, similar to companies that have divested assets to focus on core products.

Stakeholder Impact

• Shareholders face significant dilution risk from the potential issuance of new shares under the ELOC.
• Employees may be impacted by potential cost-cutting measures or restructuring.
• Customers may be affected by the company's ability to commercialize its products.
• Suppliers and creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company will continue to seek a permanent CEO and CFO.
• The company will focus on commercializing Proclarix.
• The company will explore strategic alternatives for ENTADFI, including a potential sale.
• The company will seek additional capital through various financing options.
• The company will work to obtain necessary regulatory approvals for its products.

Key Dates

Keywords

equity line of credit, ELOC, common stock, prostate cancer, Proclarix, ENTADFI, biotechnology, financing, Keystone Capital Partners, reverse stock split, PIPE financing, debt, Veru, LabCorp